Patents Examined by Nizal S. Chandrakumar
  • Synthetic progestogens and pharmaceutical compositions comprising the same
    Patent number: 11413249
    Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
    Type: Grant
    Filed: March 11, 2022
    Date of Patent: August 16, 2022
    Assignee: LABORATORIOS LEON FARMA SA
    Inventors: Philippe Perrin, Jose Luis Velada, Dominique Drouin
  • Method for the treatment of pancreatitis
    Patent number: 11413270
    Abstract: A composition for preventing and/or treating pancreatitis and a method of prevention and/or treatment of pancreatitis are disclosed. The composition include an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. The method includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: August 16, 2022
    Assignee: NOVMETAPHARMA CO., LTD.
    Inventors: Heon Jong Lee, Hoe Yune Jung, In-Kyu Lee, Jae-Han Jeon, Sung Jin Cho
  • Preparation of racemic nicotine by reaction of ethyl nicotinate with N-vinylpyrrolidone in the presence of an alcoholate base and subsequent process steps
    Patent number: 11407730
    Abstract: The present invention relates to a method of preparing racemic nicotine comprising: (i) reacting ethyl nicotinate and N-vinylpyrrolidone in the presence of an alcoholate base to 3-nicotinoyl-1-vinylpyrrolidin-2-one; (ii) reacting the 3-nicotinoyl-1-vinylpyrrolidin-2-one with an acid to myosmine; (iii) reducing the myosmine to nornicotine using a reducing agent; and (iv) methylating the nornicotine to obtain the racemic nicotine.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: August 9, 2022
    Assignees: Siegfried AG, Contraf-Nicotex-Tobacco GmbH
    Inventors: Beat Theodor Weber, Christian Lothschütz, Ben Pan
  • Methods of treating elevated plasma cholesterol
    Patent number: 11400082
    Abstract: The present invention relates to compounds of Formula I, pharmaceutically acceptable salts, solvates or formulations thereof. Compounds of Formula I increase significantly low density lipoprotein receptor and are useful for preventing and treating of elevated cholesterol.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: August 2, 2022
    Assignee: Montréal Heart Institute
    Inventors: Steve Poirier, Brent Richard Stranix, Gaétan Mayer
  • Compound for treating osteoarthritis
    Patent number: 11395815
    Abstract: The present invention relates to a compound for treating or preventing osteoarthritis. The compound relieves the joint pain, inhibits and attenuates the development of post-traumatic osteoarthritis in mouse model. The present invention also provides a pharmaceutical composition comprising the compound for treating or preventing osteoarthritis. The present invention further provides a method for treating or preventing osteoarthritis by administrating to the patient in need thereof with the pharmaceutical composition.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: July 26, 2022
    Assignees: ASCENTAGE PHARMA (SUZHOU) CO., LTD., ASCENTAGE PHARMA GROUP CORP LIMITED
    Inventors: Dajun Yang, Yifan Zhai, Douglas Dong Fang, Saijie Zhu
  • Methods of treating metabolic diseases with fused bicyclic pyrazoles
    Patent number: 11389444
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as obesity and the like.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: July 19, 2022
    Assignee: BELITE BIO, INC
    Inventors: Yu-Hsin Tom Lin, Cheng-Chi Irene Wang
  • Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
    Patent number: 11389420
    Abstract: The present invention describes the use of a NK1-antagonist, in constant combination with neostigmine, to facilitate the treatment of a patient suffering from myasthenia gravis by providing a therapeutically effective neostigmine bromide or methylsulfate daily dose without the dose-limiting gastrointestinal adverse effects.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: July 19, 2022
    Assignee: DAS-MG, Inc.
    Inventor: Kathleen Clarence-Smith
  • Chiral indole compounds and their use
    Patent number: 11390621
    Abstract: The present disclosure relates to indole compounds and pharmaceutical compositions thereof, and their use in stimulating the immune system of patients in need thereof and in treating cancer.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: July 19, 2022
    Assignee: ARIAGEN, INC.
    Inventors: Graham Johnson, Peter Colabuono, Paul Gerard Pearson, David Douglas Manning
  • Tropicamide-based ophthalmic formulations
    Patent number: 11382901
    Abstract: An ophthalmic composition includes tropicamide, at least one cyclodextrin at concentrations of less than 2.5%, at least one surfactant at concentrations of less than 2.5%. The composition is physically stable at neutral pH.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: July 12, 2022
    Assignee: FOR HEALTH PHARMA S.R.L.
    Inventor: Sebastiano Mangiafico
  • Prevention of rosacea inflammation
    Patent number: 11382890
    Abstract: The disclosure demonstrates the role of mast cell stabilizers in treating rosacea. The disclosure also shows the role of mast cells, cathelicidin, serine protease and/or vitamin D3 in rosacea pathology and the use of antagonists and inhibitors thereof to treat rosacea.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: July 12, 2022
    Assignee: The Regents of the University of California
    Inventors: Richard L. Gallo, Anna Di Nardo, Yumiko Muto
  • Method for the manufacturing of delmopinol intermediates
    Patent number: 11384056
    Abstract: The present invention relates to a new process for producing intermediates useful in the manufacture of 2-(3-(4-propylheptyl)morpholino)ethan-1-ol. The invention also relates to intermediates 1-chloro-4-propylhept-3-ene and 1-iodo-4-propyl-hept-3-ene.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: July 12, 2022
    Assignee: Lundbeck Pharmaceuticals Italy S.P.A.
    Inventors: Carla De Faveri, Mariano Stivanello
  • Aryl hydrocarbon receptor (AhR) modulator compounds
    Patent number: 11376241
    Abstract: The present invention relates to compounds which can act as aryl hydrocarbon receptor (AhR) modulators and, in particular, as AhR antagonists. The invention further relates to the use of the compounds for the treatment and/or prophylaxis of diseases and/or conditions through binding of said aryl hydrocarbon receptor by said compounds.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: July 5, 2022
    Assignee: PHENEX PHARMACEUTICALS AG
    Inventors: Christoph Steeneck, Ulrich Deuschle, Michael Albers, Thomas Hoffmann
  • Use of reboxetine to treat narcolepsy
    Patent number: 11364245
    Abstract: Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.
    Type: Grant
    Filed: August 10, 2021
    Date of Patent: June 21, 2022
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Synthetic progestogens and pharmaceutical compositions comprising the same
    Patent number: 11351122
    Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
    Type: Grant
    Filed: March 1, 2022
    Date of Patent: June 7, 2022
    Assignee: LABORATORIOS LEON FARMA SA
    Inventors: Philippe Perrin, Jose Luis Velada, Dominique Drouin
  • 3-vinylquinolines as cancer cells inhibitors
    Patent number: 11345692
    Abstract: 3-vinylquinolines analogs and methods of synthesizing the derivatives/analogs are provided. In particular, the compounds are useful for the treatment of cancer.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: May 31, 2022
    Assignee: King Abdulaziz University
    Inventors: Tarek Salah Ibrahim, Mohamed Moustafa Hawwas, Azizah M. Malebari, Moustafa E. El-Araby, Abdelsattar M. Omar
  • Methods for preparing stabilized amorphous drug formulations using acoustic fusion
    Patent number: 11344496
    Abstract: The present invention relates to methods for producing a stable amorphous dispersion of a pharmaceutically active substance having poor water solubility by applying low frequency acoustic energy to a mixture comprising the active substance and at least one polymer and heating the mixture until a stable amorphous dispersion is formed. The methods of the invention are an effective means of converting a crystalline API to a substantially amorphous and stable form, i.e., wherein the crystallinity is less than about 5%. The methods of the invention result in more complete amorphization, increased solubility, drug loading and stability as compared typical amorphization or literature methods.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: May 31, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Dennis H. Leung, Zhiqiang Guo, Christopher W. Boyce
  • Polymorph of HDAC6-selective inhibitor and application thereof
    Patent number: 11345682
    Abstract: Disclosed in the present invention are a polymorph A of a compound represented by formula (I), and an application thereof in preparation of drugs for treating HDAC6-associated diseases.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: May 31, 2022
    Assignees: CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD., CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD., CSTONE PHARMACEUTICALS
    Inventors: Qiang Guo, Changqing Wei, Yao Xiao, Lili Fan, Wenyuan Qian
  • Compositions and methods of enhancing 5-hydroxytryptophan bioavailability
    Patent number: 11337963
    Abstract: Provided are methods of enhancing bioavailability of enterally administered 5-hydroxytryptophan (5-HTP) in a subject in need thereof, said method comprising enterally co-administering low-dose carbidopa with said 5-HTP, as well as pharmaceutical formulations useful for the same. In some embodiments, the 5-HTP and/or low-dose carbidopa are provided as slow-release formulation(s).
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: May 24, 2022
    Assignee: Duke University
    Inventors: Jacob P. R. Jacobsen, Marc G. Caron
  • Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases
    Patent number: 11337946
    Abstract: Composition for promoting mitochondrial biogenesis and improving mitochondrial function in a subject, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and citric acid, succinic acid, malic acid.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: May 24, 2022
    Assignee: Professional Dietetics International S.r.l.
    Inventor: Paolo Luca Maria Giorgetti
  • Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
    Patent number: 11325889
    Abstract: Provided herein are piperidine dione compounds having the following structure: wherein RN, R1, R2, R3, R4, X, L, V, m, and n are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: May 10, 2022
    Assignee: Celgene Corporation
    Inventors: Massimo Ammirante, Sogole Bahmanyar, Matthew D. Correa, Virginia Grant, Joshua Hansen, Evan J. Horn, Timothy S. Kercher, Christopher Mayne, Mark A. Nagy, Rama Krishna Narla, Surendra Nayak, Stephen Norris, Patrick Papa, Veronique Plantevin-Krenitsky, John J. Sapienza, Brandon W. Whitefield, Shuichan Xu